BioLineRx Ltd. (NASDAQ: BLRX)
$0.78
+0.0235 ( +3.09% ) 102.5K
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Market Data
Open
$0.78
Previous close
$0.76
Volume
102.5K
Market cap
$63.23M
Day range
$0.76 - $0.80
52 week range
$0.51 - $2.53
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 3 | Sep 11, 2023 |
6-k | Quarterly Reports | 37 | Aug 30, 2023 |
6-k | Quarterly Reports | 3 | Aug 30, 2023 |
6-k | Quarterly Reports | 2 | Aug 08, 2023 |
6-k | Quarterly Reports | 3 | Jul 17, 2023 |